Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announced it received its first granted patent in Canada, marking its 28th globally. The Canadian Patent #3,093,414 pertains to transdermal and dermal delivery methods for cannabinoids, including CBD and THC. This advance opens new pharmaceutical applications and enhances skin-penetration of active ingredients. Past studies demonstrated a nearly 1,900% increase in CBD permeability using Lexaria's technology. The patent underscores Lexaria's innovation in drug delivery and strengthens its intellectual property portfolio.
Lexaria Bioscience Corp. has announced significant results from its clinical hypertension study, HYPER-H21-4. The study showed that Lexaria's DehydraTECH-CBD achieved a 45.8% higher average blood plasma CBD level (33.3 ng/mL) than published pharmaceutical-grade CBD comparators at a lower dosage (3.38 mg/kg). At the highest tested dose of 4.46 mg/kg, this level rose to 53.7 ng/mL, indicating a 141% improvement over previous formulations. CEO Chris Bunka emphasized the importance of these results for patient health outcomes and Lexaria's pursuit of FDA registration for DehydraTECH-CBD.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has initiated dosing in its human clinical study, NIC-H22-1, aimed at evaluating DehydraTECH-nicotine pouches against leading brands ON! and Zyn. This randomized, double-blinded study includes 36 participants and will assess nicotine absorption and subjective experiences. Fully funded internally, the study taps into the rapidly growing oral nicotine pouch market, projected to reach $21.84 billion by 2027. Lexaria recently secured its first patent for DehydraTECH in nicotine delivery, promising competitive advantages in this space.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announces that its patented DehydraTECH-CBD has shown enhanced effectiveness compared to Epidiolex in animal studies. The initial pilot study indicated that at lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH-CBD was more effective than Epidiolex in reducing seizure activity. The secondary study revealed faster onset of action for DehydraTECH-CBD, with effective results observed at 30 and 60 minutes post-dosing. Lexaria plans to continue optimizing DehydraTECH-CBD formulations and conducting further studies to establish definitive dosing metrics.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is set to launch its study program DEM-A22-1 on November 15, 2022, investigating DehydraTECH-processed CBD for potential therapeutic effects against dementia. Previous studies have shown CBD's efficacy in managing hypertension, a risk factor for vascular dementia. The upcoming study will include 32 Long Evans rats and aims to assess cognitive performance through a novel object recognition test. Results are anticipated in April 2023. The dementia treatment market is projected to grow from $15.5 billion in 2021 to $32.3 billion by 2030.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched study DIAB-A22-1 to explore the therapeutic potential of its DehydraTECH-processed CBD for diabetes. The research involves 32 male Zucker rats over 56 days to assess weight gain, blood glucose, cholesterol, and triglyceride levels. Lexaria's technology has previously shown promise in hypertension. The diabetes market is significant, with global device and drug markets estimated at $26.7 billion and $63.1 billion, respectively. Results from the study are expected in early January 2023.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced IRB approval for its upcoming human clinical study NIC-H22-1, comparing its DehydraTECH-nicotine pouch to leading brands ON! and Zyn. The 36-person study will evaluate various metrics, including nicotine absorption and user experience. Previous studies indicate DehydraTECH technology may enhance nicotine delivery, achieving up to 20x faster absorption. With the oral nicotine pouch market projected to grow from $2.33 billion in 2020 to $21.84 billion by 2027, Lexaria aims to capitalize on this trend with its patented technology.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced positive results from its human clinical study HYPER-H21-4, demonstrating significant and sustained blood pressure (BP) reductions in hypertensive patients using its DehydraTECH-CBD formulation. Key findings include an average systolic BP reduction of up to 7.01 mmHg over five weeks, with no serious adverse events reported. The study suggests potential additive BP lowering effects for patients on standard medications. Lexaria plans to advance into a Phase Ib clinical study with the U.S. FDA.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced the appointment of Dr. Catherine Turkel to its board of directors, enhancing its leadership at a pivotal time. Dr. Turkel brings over 20 years of experience in the pharma and biotech sector, notably leading global drug development programs. Her expertise in regulatory strategy and commercial planning, particularly with Allergan's BOTOX program, is expected to advance Lexaria's DehydraTECH technology, which enhances the delivery of active pharmaceutical ingredients. Lexaria is positioned for continued growth following a successful pre-IND meeting with the FDA.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced the granting of its 27th international patent in Mexico under registration #390001. This patent is part of Lexaria's third patent family, covering Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, which has also received recognition in Australia, India, and Japan. The patent allows the use of DehydraTECH-processed non-psychoactive cannabinoids to treat various disorders, including hypertension and neurological diseases. Lexaria continues its regulatory pursuit for DehydraTECH-CBD in pharmaceutical applications.